NECT is next: Implementing the new drug combination therapy for trypanosoma brucei gambiense sleeping sickness

PLoS Neglected Tropical Diseases

Volumn 4, Issue 5, 2010, Pages

  Yun, Oliver ^a   Priotto, Gerardo ^b   Tong, Jacqueline ^a   Flevaud, Laurence ^a   Chappuis, François ^a,c  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b EPICENTRE   (France)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; MELARSOPROL; NIFURTIMOX; ANTIPROTOZOAL AGENT;

AFRICAN TRYPANOSOMIASIS; ARTICLE; BRAIN DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; DRUG UTILIZATION; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HUMAN; INJECTION SITE PAIN; MEDICAL EDUCATION; MONOTHERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; AFRICA SOUTH OF THE SAHARA; DRUG COMBINATION; DRUG EFFECT; ENDEMIC DISEASE; REVIEW; TRYPANOSOMA;

AFRICA SOUTH OF THE SAHARA; ANTIPROTOZOAL AGENTS; DRUG THERAPY, COMBINATION; EFLORNITHINE; ENDEMIC DISEASES; HUMANS; NIFURTIMOX; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

EID: 77954978118     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000720     Document Type: Article

References (34)

1. World Health Organization (2006) Human African trypanosomiasis (sleeping sickness): Epidemiological update. Wkly Epidemiol Rec 8: 71-80. Available: http://www.who.int/wer/2006/wer8108/en/index.html. Accessed 11 December 2009.
2. Simarro PP, Jannin J, Cattand P (2008) Eliminating human African trypanosomiasis: where do we stand and what comes next? PLoS Med 5: e55. doi:10.1371/journal.pmed.0050055.
3. World Health Organization (2010) Neglected tropical diseases. Innovative and Intensified Disease Management (IDM). Available: http://www.who.int/neglected_diseases/disease_management/en/. Accessed 11 December 2009.
4. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Ehrlich Sachs S, et al. (2007) Control of neglected tropical diseases. N Engl J Med 357: 1018-1027.
5. World Health Organization (2009) Improving access to the best treatment for second stage T.b.gambiense. WHO presentation at 6th European Congress on Tropical Medicine and International Health, 6-10 September 2009, Verona, Italy. Available: http://www.who.int/neglected_diseases/disease_management/hat_access_trea tment/en/index.html. Accessed 7 April 2010.
6. World Health Organization (2009) WHO includes combination of eflornithine and nifurtimox in its Essential List of Medicines for the treatment of human African trypanosomiasis. Available: http://www.who.int/neglected_diseases/disease_management/drug_combinatio n/en/index.html. Accessed 11 December 2009.
7. World Health Organization (2009) WHO Technical Report Series - The Selection and Use of Essential Medicines, March 2009. Available: http://www.who.int/selection_medicines/committees/expert/17/WEB_TRS_DEC_ 2009.pdf. Accessed 7 April 2010.
8. Janssens PG, De Muynck A (1977) Clinical trials with "nifurtimox" in African trypanosomiasis. Ann Soc Belg Med Trop 57: 475-480.
9. Moens F, De Wilde M, Ngato K (1984) [Clinical trial of nifurtimox in human African trypanosomiasis.] Ann Soc Belg Med Trop 64: 37-43. [French].
10. Pepin J, Milord F, Meurice F, Ethier L, Loko L, Mpia B (1992) High-dose nifurtimox for arsenoresistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg 86: 254-256.
11. Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, et al. (2006) Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials 1: e39. doi:10.1371/journal. pctr.0010039.
12. Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, et al. (2007) Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis 1: e64. doi:10.1371/journal.pntd.0000064.
13. Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, et al. (2007) Nifurtimox- eflornithine combination therapy for second- stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 45: 1435-1442.
14. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, et al. (2009) Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374: 56-64.
15. Opigo J, Woodrow C (2009) NECT trial: more than a small victory over sleeping sickness. Lancet 374: 7-9.
16. Robays J, Raguenaud ME, Josenando T, Boelaert M (2008) Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola. Trop Med Int Health 13: 265-271.
17. Barrett MP, Boykin DW, Brun R, Tidwell RR (2007) Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 152: 1155-1171.
18. Drugs for Neglected Diseases initiative (2009) Clinical study to assess the tolerability, feasibility and effectiveness of nifurtimox and eflornithine (NECT) for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT) in the meningo-encephalitic phase (NECTFIELD). ClinicalTrials.govIdentifier: NCT00906880. http://clinicaltrials.gov/ct2/show/NCT00906880.
19. Morris K (2009) New treatment for sleeping sickness still not implemented. Lancet Infect Dis 9: 732-733.
20. Brun R, Blum J, Chappuis F, Burri C (2009) Human African trypanosomiasis. Lancet 375: 148-159.
21. Pepin J, Milord F, Khonde AN, Niyonsenga T, Loko L, et al. (1995) Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 89: 92-97.
22. World Health Organization (1998) Control and surveillance of African trypanosomiasis: Report of a WHO expert committee. WHO Technical Report Series 881. Geneva: WHO. World Health Organ Tech Rep Ser 881: 1-114.
23. Seixas J Investigations on the encephalopathic syndrome during melarsoprol treatment of human African trypanosomiasis. PhD thesis, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, 2004.
24. Schmid C, Richer M, Bilenge CMM, Josenando T, Chappuis F, et al. (2005) Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis 191: 1922-1931.
25. Burri C, Keiser J (2001) Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health 6: 412-420.
26. Legros D, Evans S, Maiso F, Enyaru JC, Mbulamberi D (1999) Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 93: 439-442.
27. Mumba Ngoyi D, Lejon V, Pyana P, Boelaert M, Ilunga M, et al. (2010) How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 201: 453-463.
28. Gyapong JO, Gyapong M, Yellu N, Anakwah K, Amofah G, et al. (2010) Integration of control of neglected tropical diseases into health-care systems: challenges and opportunities. Lancet 375: 160-165.
29. Drugs for Neglected Diseases initiative (2009) Human African trypanosomiasis: Target Product Profile (TPP). Available: http://www.dndi.org/diseases/hat/target-product-profile.html. Accessed 26 January 2010.
30. Drugs for Neglected Diseases initiative (2009) DNDi receives $15M from the Bill and Melinda Gates Foundation. The grant will advance development of a promising new medicine against sleeping sickness. Press release, November 20, 2009. Available: http://www.dndi.org/pressreleases/2009/566-dndi-receives-15m-from-thebil l-and-melinda-gates-foundation.html. Accessed 8 January 2010.
31. Lutumba P, Meheus F, Robays J, Miaka C, Kande V, et al. (2007) Cost-effectiveness of algorithms for confirmation test of human African trypanosomiasis. Emerg Infect Dis 13: 1484-1490.
32. Lutumba P, Robays J, Miaka C, Kande V, Simarro PP, et al. (2005) [The efficiency of different detection strategies of human African trypanosomiasis by T. b. gambiense.] Trop Med Int Health 10: 347-356. [French].
33. Foundation for Innovative New Diagnostics (FIND) (2010) Developing tools for disease staging. Available: http://www.finddiagnostics.org/programs/hat/find_activities/staging.html . Accessed 7 April 2010.
34. Chappuis F, Lima MA, Flevaud L, Ritmeijer K (2010) Human African trypanosomiasis in areas without surveillance [letter]. Emerg Infect Dis 16: 354-356.